Pioneering technologies that create novel antibody therapeutics to treat cancer and other serious diseases.
Research
Innovation
Discover how ÐǺ£ÆåÅÆ makes a positive impact for patients, communities, employees and the environment
Corporate and financial resources for ÐǺ£ÆåÅÆ investors, potential shareholders and analysts
Resources
Financials
Stock Information
Governance
NationalityDutch
Dr. van de Winkel is a co-founder of ÐǺ£ÆåÅÆ and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. Dr. van de Winkel has more than 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to ÐǺ£ÆåÅÆ. He is the author of over 300 scientific publications and has been responsible for over 150 patents and pending patent applications.
Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University and also holds M.S. and Ph.D. degrees from the University of Nijmegen.
Dr. van de Winkel is a registered manager of ÐǺ£ÆåÅÆ with the Danish Business Authority.